Computational Language Assessment in patients with speech, language, and communication impairments

Speech, language, and communication symptoms enable the early detection, diagnosis, treatment planning, and monitoring of neurocognitive disease progression. Nevertheless, traditional manual neurologic assessment, the speech and language evaluation standard, is time-consuming and resource-intensive for clinicians. We argue that Computational Language Assessment (C.L.A.) is an improvement over conventional manual neurological assessment. Using machine learning, natural language processing, and signal processing, C.L.A. provides a neuro-cognitive evaluation of speech, language, and communication in elderly and high-risk individuals for dementia. ii. facilitates the diagnosis, prognosis, and therapy efficacy in at-risk and language-impaired populations; and iii. allows easier extensibility to assess patients from a wide range of languages. Also, C.L.A. employs Artificial Intelligence models to inform theory on the relationship between language symptoms and their neural bases. It significantly advances our ability to optimize the prevention and treatment of elderly individuals with communication disorders, allowing them to age gracefully with social engagement.Comment: 36 pages, 2 figures, to be submite

How to do things with (thousands of) words: Computational approaches to discourse analysis in Alzheimer's disease.

Natural Language Processing (NLP) is an ever-growing field of computational science that aims to model natural human language. Combined with advances in machine learning, which learns patterns in data, it offers practical capabilities including automated language analysis. These approaches have garnered interest from clinical researchers seeking to understand the breakdown of language due to pathological changes in the brain, offering fast, replicable and objective methods. The study of Alzheimer's disease (AD), and preclinical Mild Cognitive Impairment (MCI), suggests that changes in discourse (connected speech or writing) may be key to early detection of disease. There is currently no disease-modifying treatment for AD, the leading cause of dementia in people over the age of 65, but detection of those at risk of developing the disease could help with the identification and testing of medications which can take effect before the underlying pathology has irreversibly spread. We outline important components of natural language, as well as NLP tools and approaches with which they can be extracted, analysed and used for disease identification and risk prediction. We review literature using these tools to model discourse across the spectrum of AD, including the contribution of machine learning approaches and Automatic Speech Recognition (ASR). We conclude that NLP and machine learning techniques are starting to greatly enhance research in the field, with measurable and quantifiable language components showing promise for early detection of disease, but there remain research and practical challenges for clinical implementation of these approaches. Challenges discussed include the availability of large and diverse datasets, ethics of data collection and sharing, diagnostic specificity and clinical acceptability

Marqueurs discursifs de neurodégénérescence liée à la pathologie Alzheimer

La maladie d’Alzheimer (MA) et les aphasies progressives primaires (APP) s’accompagnent de perturbations du langage expressif parfois subtiles, mais précoces dans l’évolution de ces maladies neurodégénératives. Considérés dans une approche automatisée, ces changements pourraient constituer des marqueurs de dégénérescence identifiés de façon non invasive et peu onéreuse. À ce titre, ils font l’objet d’études visant à automatiser leur utilisation clinique. Cependant, l’intégration des marqueurs langagiers à une approche diagnostique centrée sur les biomarqueurs reste à faire. À cette fin, la présente thèse a deux objectifs. D’abord, recenser systématiquement les marqueurs du discours qui distinguent le mieux les personnes avec une MA de témoins en santé. Ensuite, appliquer une approche automatisée et à un large éventail de marqueurs de discours pour identifier, dans un groupe hétérogène de patients avec une APP, lesquels ont une pathologie Alzheimer sous-jacente. Afin de mettre en contexte ces deux objectifs, nous proposons une introduction générale comprenant les éléments suivants : la pathophysiologie de la MA et des APP, le rôle croissant des biomarqueurs dans la prise de décision clinique dans les maladies neurodégénératives, les études pionnières du discours en neurodégénérescence, ainsi que de récentes études computationnelles sur les marqueurs de discours dans la MA et les APP. Nos résultats font émerger un patron multidimensionnel (acoustique, lexical, syntaxique, sémantique et pragmatique) de changements langagiers qui distinguent les personnes avec une MA de témoins en santé, avec une prépondérance des marqueurs lexicosémantiques. Dans le groupe de patients avec une APP avec une imagerie amyloïde positive ou négative, nous mesurons ensuite le pouvoir de classification d’un court échantillon de discours et montrons qu’il peut être avantageusement comparé à d’autres biomarqueurs. Nous discutons du patron spécifique de marqueurs discriminants pour ce sous-groupe de patients, notamment l’importance des marqueurs psycholinguistiques pour prédire le résultat de l’imagerie amyloïde à partir du discours.Alzheimer’s disease (AD) and primary progressive aphasias (PPA) feature changes in expressive language that appear early in the course of the disease. Within an automated analysis framework, these language changes could offer a non-invasive and inexpensive alternative to the collection of biomarkers which are not readily available in most settings. Current research is thus focused on the automated analysis of language data for clinical use. The usefulness of connected speech (CS) markers has not yet been established in a diagnostic perspective focused on biomarkers. To this aim, the present thesis contains two phases. First, we systematically review the CS markers that best differentiate persons with AD from healthy controls. Second, we automatically extract a wide array of CS markers in a heterogenous group of PPA patients by combining expert knowledge and the latest natural language processing software. A machine-learning classification approach identifies PPA patients for the presence of underlying AD pathology. The most discriminant CS features are identified. To integrate the two phases of the thesis, we provide a general introduction with the following sections: the pathophysiology of AD and PPAs, the growing importance of biomarkers in clinical decision-making for neurodegenerative diseases, the seminal studies of CS in neurodegenerative diseases, and the latest computational studies of CS markers in AD and PPA. Our results bring forth a multidimensional pattern (acoustic, lexical, syntactic, semantic, pragmatic) of language changes that distinguish people with AD from healthy controls, with an emphasis on lexical-semantic features. In the group of PPA patients with either positive or negative amyloid imaging, we then describe the classificatory power of a short sample of CS and show that it compares favorably to other biomarkers. We discuss the specific pattern of discriminant markers for this subgroup of patients, in particular the role of psycholinguistics